The estimated Net Worth of Donald Russell is at least $37.5 mil dollars as of 13 January 2012. Donald Russell owns over 5,000 units of AIM ImmunoTech Inc stock worth over $37,517 and over the last 19 years Donald sold AIM stock worth over $0.
Donald has made over 1 trades of the AIM ImmunoTech Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Donald bought 5,000 units of AIM stock worth $15,350 on 13 January 2012.
The largest trade Donald's ever made was buying 5,000 units of AIM ImmunoTech Inc stock on 13 January 2012 worth over $15,350. On average, Donald trades about 185 units every 0 days since 2006. As of 13 January 2012 Donald still owns at least 121,063 units of AIM ImmunoTech Inc stock.
You can see the complete history of Donald Russell stock trades at the bottom of the page.
Donald's mailing address filed with the SEC is 1212 N Hercules Ave, Clearwater, FL 33765, USA.
Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over $15,026,013 worth of AIM ImmunoTech Inc stock and bought 898,126 units worth $656,210 . The most active insiders traders include Thomas K Equels, J Mervyn Nabors, eCommercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of $16,943. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth $25,309.
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
AIM ImmunoTech Inc executives and other stock owners filed with the SEC include: